Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Revenue ContractionContracting
Percentile Rank31
3Y CAGR-78.0%
5Y CAGR-50.9%
Studio
Year-over-Year Change

Total revenue from sales of goods and services

3Y CAGR
-78.0%/yr
vs -0.4%/yr prior
5Y CAGR
-50.9%/yr
Recent deceleration
Acceleration
-77.6pp
Decelerating
Percentile
P31
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$192000.00-56.5%
2024$441000.00-77.1%
2023$1.92M-89.3%
2022$18.05M+234.4%
2021$5.40M-19.4%
2020$6.70M-0.8%
2019$6.75M-63.2%
2018$18.33M-34.1%
2017$27.81M+2312.2%
2016$1.15M-